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Immunodominant and public T cell receptor (TCR)
usage is relatively common in many viral diseases
yet surprising in the context of the large naive TCR
repertoire. We examined the highly conserved
Vb17:Va10.2 JM22 T cell response to the influenza
matrix peptide (58-66)-HLA-A*0201 (HLA-A2-flu)
through extensive kinetic, thermodynamic, and
structural analyses. We found several conforma-
tional adjustments that accompany JM22-HLA-A2-
flu binding and identified a binding ‘‘hotspot’’ within
the Vb domain of the TCR. Within this hotspot, key
germline-encoded CDR1 and CDR2 loop residues
and a crucial but commonly coded residue in the
hypervariable region of CDR3 provide the basis for
the substantial bias in the selection of the germline-
encoded Vb17 domain. The chances of having a
substantial number of T cells in the naive repertoire
that have HLA-A2-flu-specific Vb17 receptors may
consequently be relatively high, thus explaining the
immunodominant usage of this clonotype.
INTRODUCTION
The cytotoxic T lymphocyte response to the HLA-A*0201 influ-
enza-virus matrix peptide (amino acids 58–66, sequence
GILGFVFTL) complex (HLA-A2-flu) is dominated by T cell recep-
tors (TCRs) of the Vb17 clonotype (Bowness et al., 1993; Gotch
et al., 1987; Lawson et al., 2001a, 2001b; Lehner et al., 1995;
Morrison et al., 1992; Moss et al., 1991). Vb17 immunodomi-
nance emerges through repeated influenza-virus infections, indi-
cating that Vb17-bearing TCRs offer particularly good solutions
to the problem of peptide-major histocompatability complex
(pMHC) binding in the context of T cell proliferation and T cell
memory, rather than being the consequence of an initial bias in
the peripheral repertoire (Lawson et al., 2001a, 2001b). The
high-resolution crystal structure of the Vb17 TCR-HLA-A2-flu
complex (Stewart-Jones et al., 2003) confirmed that the Vb17-bearing receptor JM22 conforms to general rules of TCR-
pMHC docking, including an orthogonal binding mode, and
revealed clues to the structural basis for the predominant use
of the Vb17 domain in HLA-A2-flu recognition. The immunodomi-
nant TCRs are characterized by a highly selected amino acid
sequence in the CDR3b loop displaying variable codon usage
and typically consisting of arginine-serine-serine-tyrosine
(RSSY), although some sequence variations, for example argi-
nine-glycine-alanine-tyrosine (RGAY), have been reported
(Lehner et al., 1995). The JM22 structure contains the RSSY
motif, and the complex reveals that the highly conserved arginine
at position 98 and serine at position 99 dock into a notch formed
between the HLA-A2 and the flat ‘‘plain vanilla’’ flu peptide
(Davis, 2003; Stewart-Jones et al., 2003). Additionally, the Q52
and D32 side chains in CDR2b and CDR1b hydrogen bond to
the peptide, and the combination of these two residues is unique
to the Vb17 sequence. As a well-characterized immunodominant
response, emerging over multiple rounds of infection and clonal
selection, the binding of the Vb17 clonotype (exemplified by
JM22) to HLA-A2-flu is a highly selected interaction and a
good model for human T cell immunodominance.
Exactly how TCR-pMHC binding leads to successful T cell
activation, proliferation, andmemory generation is still uncertain.
T cell activation has been correlated with a variety of TCR-pMHC
binding properties in solution, including the half-life (dissociation
rate contant or koff) (Matsui et al., 1994; Savage et al., 1999), the
heat capacity change (Krogsgaard et al., 2003), and the number
of sequential binding events that occur in a given time (serial trig-
gering) (Valitutti and Lanzavecchia, 1997; Valitutti et al., 1995).
Further, the mechanism of TCR triggering remains controversial
(reviewed in Choudhuri and van der Merwe [2007]), and vital
aspects of the process remain to be elucidated.
Structures of TCR-pMHC complexes show a semiconserved
diagonal binding mode with the Va and Vb domains positioned
over the peptide N- and C-terminal halves, respectively (Gar-
boczi et al., 1996; Garcia et al., 1996, 1999; Rudolph et al.,
2006; Stewart-Jones et al., 2003; Turner et al., 2006). Individual
crystal structures represent ‘‘snapshots’’ raising the question of
how physiological the structures are. Recently, Tynan et al. re-
ported that a TCR binding to a super-bulged 13-mer peptide
presented by human leucocyte antigen (HLA) B*3508 couldImmunity 28, 171–182, February 2008 ª2008 Elsevier Inc. 171
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however, to which this observation may be generalized to other
TCR-pMHC complexes and its significance for the process of
T cell-antigen recognition remain undefined.
Surface-plasmon resonance (SPR) studies have provided
kinetic and thermodynamic insights into the process of TCR
binding. These interactions are generally weak and of slow kinet-
ics relative to cell-cell surface interactions with comparable affin-
ities (van der Merwe and Davis, 2003). TCR-pMHC binding is
generally driven by favorable enthalpic changes that overcome
an entropic penalty, although an exception has been noted (Ely
et al., 2006). The ‘‘energetic landscapes’’ of some TCR foot-
prints, including those specific for the human T cell leukemia
virus type-1 and the Epstein-Barr virus (EBV), have been dis-
sected by TCRmutagenesis and binding studies at a nonphysio-
logical temperature (25C), and contributions from all three CDR
loops have been identified in different studies (Borg et al., 2005;
Gagnon et al., 2003, 2005; Kersh et al., 1998; Lee et al., 2000;
Manning et al., 1998). Conformational change in the JM22 TCR
has been inferred from a large entropic penalty for binding (Will-
cox et al., 1999) and from published unliganded and liganded
TCR structures. Conformational changes can range from large
(KB5-C20) (Reiser et al., 2002) to small (1G4) (Chen et al.,
2005). Generally, the CDR3 loops undergo greatest conforma-
tional change (Chen et al., 2005; Garcia et al., 1996; Kjer-Nielsen
et al., 2003; Reiser et al., 2002).
We addressed several unresolved issues in JM22-HLA-A2-flu
binding, including (1) which residues are responsible for the
binding affinity and how this relates to TCR immunodominance,
and (2) the role of flexibility and conformational change before
and after TCR binding. To this end, we undertook 22 kinetic
analyses and ten thermodynamic analyses of TCR mutants.
Our results revealed an energetic ‘‘hotspot’’ of binding within the
interaction interface with a crucial involvement of the germline-
encoded Vb17 framework as well as R98 in the CDR3b. We
also analyzed five liganded TCR complexes—the unliganded
JM22, and a mutant JM22(S99A) complex—that provided a se-
ries of crystallographic ‘‘snapshots’’ of the JM22 receptor before
and after binding. We observed a series of conformational
adjustments in the TCR, including a scissoring motion of the
Va domain, readjustment of the interfacial water structure, and
stabilization of the CDRs on binding. A pivoting, or ‘‘rocking,’’
motion centered on the binding hotspot is revealed from the
structures of JM22:HLA-A2-flu complex crystal forms. Most of
the recognition is encoded by the germline of Vb17, with the
notable exception of the R98 residue in the hypervariable por-
tion of CDR3b, suggesting that although much of the striking im-
munodominance of Vb17 may be attributed to a pre-existing
fit for HLA-A2-flu, some adaptation in the hypervariable region
is crucial.
RESULTS
Crystal Structures of pMHC, Unliganded,
and Complexed TCR
Soluble forms of the JM22 TCR and the HLA-A2-flu were
separately refolded, purified, and crystallized as unliganded
components or as a complex. Numerous conditions yielded
crystals of the TCR-pMHC complex. Datasets were collected,172 Immunity 28, 171–182, February 2008 ª2008 Elsevier Inc.and structures refined (resolution, Rcryst, Rfree in parentheses)
for the JM22 TCR crystals (1.96 A˚, Rcryst = 20.4, Rfree = 27.9),
HLA-A2-flu (1.6 A˚, Rcryst = 19.1, Rfree = 24.2), and two unique
(i.e., additional to the 1.4 A˚ resolution complex) crystal forms
for the JM22:HLA-A2-flu complex (2.4 A˚, Rcryst = 19.6, Rfree =
27.2 and 2.5 A˚, Rcryst = 21.8, Rfree = 28.8) plus a complex with
the mutant VbS99A JM22:HLA-A2-flu (2.3 A˚, Rcryst = 21.9, Rfree =
28.1) were collected (Table 1). The unliganded TCR and the 2.4
A˚ and 2.5 A˚ TCR-pMHC complex crystal structures had one mol-
ecule or complex per crystallographic asymmetric unit, whereas
the unliganded HLA-A2-flu, the 2.3 A˚ JM22(S99bA):HLA-A2-flu
complex, and the 3.6 A˚ resolution JM22:HLA-A2-flu complex
crystal structure all contained two copies. Molecular replacement
followedby rigid-body refinement indicated that the relative orien-
tations of pMHCandTCR for both copies of the complex in the 3.6
A˚ resolution crystal structure fell within a range seen in the higher-
resolution complexes (see below), and, given the limited resolu-
tion, this crystal form is therefore not discussed further. Lattice
contacts did not involve the peptides in either of the two copies
of the HLA-A2-flu structure, thus providing unbiased views of
the epitope structure and associated hydration shell. Overall, we
present a complete series of structures of the pre- and postbound
statesof these receptorsat high resolutionandmultiple snapshots
of the TCR-MHC complex in different crystal forms. This provided
a substantial set of structural data fromwhich several key charac-
teristics for theprocessof TCR-pMHCrecognition in this immuno-
dominant system can be distilled.
Conformational Changes upon Binding
The JM22 TCR underwent two distinct types of conformational
change on binding HLA-A2-flu: a marked scissoring effect of
the variable domains (Figure 1A) and a CDR3-loop repositioning
(Figures 1B and 1C). Whereas the repositioning of the CDR3a
and CDR3b loops is consistent with observations from previous
studies, where structures of unliganded and liganded TCRs are
available (Chen et al., 2005; Garcia et al., 1996; Kjer-Nielsen
et al., 2003; Reiser et al., 2002), the magnitude of the JM22
Va:Vb scissoring motion was considerably greater than any
previous observation. Unusually, the high-resolution of the struc-
tures permitted direct observation of changes, on binding, in the
water structure associated with the pMHC; some water mole-
cules remained semifixed, whereas others moved to new posi-
tions or were ejected from the surface (Figure 1D).
Superimposing all JM22 TCR structures via the beta chain
showed the Va domain hinges in a scissoring motion in the vicin-
ity of the Q38a-Q39b salt bridge near the Va:Ca linker region
(residues 110–113). The Va domain changed orientation with
respect to the Vb domain by approximately 7.0 on binding the
HLA-A2-flu (Figure 1A). The hydrophobic core side chains (Table
S1 available online) in the Va:Vb domain interface did not show
markedly altered conformations in switching between these
two states; however, each state was stabilized by numerous
unique interdomain contacts. Many of the conserved Va:Vb
interface contacts comparing bound and unbound states were
hydrophobic, facilitating the scissoring. Although not all Va10.2
TCR V framework residues that contact the Vb17 TCR V frame-
work were unique to Va10.2, the combination of residues S34,
Y36, Q38, G41, E42, G43, P44, L46, and T49—which are from
the Va10.2 TCR V framework and contact the Vb17 domain—is
Immunity
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preferentially coselected with the Vb17-R98S99 domain. This
Va-Vb relative reorientation indicates that the V domains of the
JM22 immunodominant TCR can undergo similar structural
changes to those of antibody V domains on binding antigens
(Colman, 1988), providing a further parameter to optimize the
fit of a TCR to its cognate pMHC.
The structures of the constant domains in the three crystal
structures of the liganded JM22 were almost identical; however,
the unliganded JM22 showed considerable structural differ-
ences (Figure S3). The anticlockwise scissoring motion of the
Vadomain on theVbdomain appeared linked to a conformational
change into the Ca, which undergoes substantial rearrange-
ments. In particular, the disordered regions in the unliganded
structure (a145–a148 and a158–a170), which were omitted
from the refined coordinates because of lack of electron density,
became ordered in the liganded complexes.
Superimposition of individual V domains in bound and
unbound states illustrates that both CDR3 loops undergo
marked conformational change in the antigen-combining site,
whereas CDR1 and CDR2 loops underwent almost no change.
Although the CDR3 loops of the unbound JM22 structure were
involved in contacts to neighboring molecules in the crystal—molecules that may have influenced the selection and stability
of the observed conformations—the implication is that in un-
bound JM22 the CDR3 loops can adopt one or more conforma-
tions that differ from those required to bind HLA-A2-flu. Between
bound and unbound structures, the whole of the CDR3a loop
swiveled by some 8, and the main-chain atoms at the apex
moved by5 A˚ (Figure 1B). The tip of the CDR3b loop underwent
a repositioning of some 5 A˚ in the main chain (Figure 1C). Some
Vb17 framework side chains readjusted slightly (e.g., F30a) on
binding pMHC. The side chains bearing the conserved CDR3b
RSSY (98–101) motif found in nearly all Vb17 TCRs responding
to HLA-A2-flu were radically reorientated on binding (Figure
S2). The R98b guanadinium headgroup is repositioned by some
7 A˚, enabling it to dock into a ‘‘notch’’ (Stewart-Jones et al.,
2003) formed between the HLA-A2 a2 helix and the peptide,
the S99b is also repositioned by 7 A˚, and the side chain of
Y101b underwent a near 180 flip from between the CDR3
loops to interact with the a2 helix.
Very subtle changes in the conformation of the peptide could
be observed on ligation of the pMHC with the JM22. The side
chain of Q155, previously considered as a ‘‘gatekeeper’’ (Tynan
et al., 2005) side chain on the a2 helix, underwent a switch in con-
formation on JM22 binding, allowing the conserved CDR3b R98Table 1. Crystallographic Statistics
Data Collection JM22-A2-flu (2.4 A˚) JM22-A2-flu (2.5 A˚) HLA-A2-flu JM22 TCR JM22-A2-flu (S99A)
Space Group C2 C2 P1 P61 P1
Unit-cell dimensions
(A˚) (a, b, g)
175.2, 48.2, 119.0 211.3, 47.9, 113.1 49.1, 61.9, 73.8 86.8, 86.8, 110.3 47.7, 93.4, 118.3
Angles () (a, b, g) 90, 110, 90 90, 112, 90 82, 76, 78 90, 90, 120 110, 98, 95
Source ESRF ID14-eh2 ESRF ID14-eh2 ESRF ID14-eh2 ESRF ID14-eh2 ESRF ID14-eh2
Resolution (A˚)
(highest-resolution shell)
30–2.4 (2.51–2.40)* 30–2.5 (2.59–2.50)* 30–1.6 (1.64–1.60)* 30–1.98 (2.03–1.98)* 30–2.3 (2.38–2.30)*
Measured reflections 333392 458541 680266 953034 1032287
Unique reflections 37484 40395 100261 31111 87500
Completeness (%) 98.8 (90.8)* 99.8 (99.9)* 89.7 (62.4)* 93.3 (99.4)* 97.5 (96.1)*
I/s (I) 17.7 (2.8)* 10.3 (2.3)* 22.0 (2.9)* 36.1 (3.92)* 10.7 (1.75)*
Rmerge (%)
a 11.4 (51.7)* 11.6 (78.9)* 3.8 (27.8)* 6.4 (68.2)* 9.7 (56.2)*
Refinement Statistics
Resolution range (A˚) 30–2.4 (2.51–2.40)* 30–2.5 (2.59–2.50)* 30–1.6 (1.64–1.60)* 30–1.6 (1.64–1.60)* 30–2.3 (2.38–2.30)*
Rcryst
b 19.6 21.8 19.1 20.4 21.9
Rfree
c 27.2 28.8 24.2 27.9 28.1
Number of non-H
protein atoms
6833 6833 7420 3725 13827
Number of water molecules 331 215 1208 337 584
Rms deviation from ideality
Bond lengths (A˚) 0.017 0.015 0.011 0.013 0.018




(86.2, 12.2, 0.8, 0.8) (86.0, 12.1, 1.2, 0.7) (92.0, 7.7, 0.3, 0.0) (88.0, 11.1, 0.5, 0.3) (87.3, 11.1, 0.9, 0.6)
*Numbers in parentheses correspond to the outermost shell of data.
a Rmerge = ShkljI  < I > j/ShklI where I is the intensity of unique reflection hkl and < I > is the average over symmetry-related observation of unique
reflection hkl.
b Rcryst = SjFobs  Fcalcj/SFobs where Fobs and Fcalc are the observed and calculated structure factors, respectively.
c Rfree is calculated as for Rcryst but with 5.0% of reflections sequestered before refinement.Immunity 28, 171–182, February 2008 ª2008 Elsevier Inc. 173
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between the crest of the a2 helix and the peptide. Although the
unliganded HLA-A2-flu structure was previously determined to
2.5 A˚ resolution (Madden et al., 1993) in a different crystal form
and the peptide structures were broadly identical, the higher res-
olution allowed refinement of many water molecules associated
to the complex.
Of the total of nine pMHC-associatedwater molecules present
at the TCR binding surface of the unliganded HLA-A2-flu, five
were either markedly shifted or ejected from the interface on
TCR binding, whereas four water molecules remained broadly
fixed (Figure 1D). Few water molecules were tightly bound to
the unliganded TCR CDR loops, and none corresponded with
the positions found at the interface. The water molecules at the
interface acted as ‘‘molecular glue’’ and formed hydrogen-bond-
ing bridges between the epitope and the TCR. The water trap-
ping will contribute to the entropic penalty indicated by the ther-
modynamic data for wild-type (WT) JM22 binding (Willcox et al.,
1999), and changes in hydrogen-bond numbers and distribution
were likely to contribute to the substantial thermodynamic differ-
ences observed for many of the JM22mutants described below.
SPR studies have indirectly indicated that TCR interactions
with pMHC involve the stabilization of a flexible recognition
interface (Willcox et al., 1999). Our high-resolution structures of
the unliganded HLA-A2-flu complex (1.6 A˚), JM22 TCR (1.96
A˚), and JM22:HLA-A2-flu (1.4 A˚) permitted the direct observation
of changes in temperature-factor distribution (a reflection of
degree of conformational variation) on binding and thus allowed
us to study this stabilization in detail. A substantial reduction in
temperature factors was most apparent in the CDR-loop atoms
engaged on formation of the complex but also extended into
the Vb17:Va10.2 framework (Figure 1E). This stabilization
reflects an entropy reduction that is compensated by the
favorable enthalpic gain of forming numerous interprotein inter-
actions. Additionally, water molecules trapped within the inter-
face displayed low temperature factors similar to those of the
protein atoms (B 18 A˚2) yet formed hydrogen bonds and thus
were likely to contribute to the large, balanced entropic and
enthalpic changes that accompany JM22 recognition (Willcox
et al., 1999).174 Immunity 28, 171–182, February 2008 ª2008 Elsevier Inc.Biophysical Characterization of Immunodominant
TCR-pMHC Binding
Using the previously characterized 1.4 A˚ JM22-HLA-A2-flu com-
plex structure and sequence analysis of Vb17-bearing clones
(Lehner et al., 1995; Stewart-Jones et al., 2003), we identified
twelve key contact amino acids and mutated these residues to
alanine, glycine, or a similar residue in order to assess their
contribution to binding (Figure 2). Only TCR residues with side
chains that contacted the pMHCwere selected for mutagenesis.
The effects of these mutations on the affinity, kinetics, and ther-
modynamics of binding were determined by SPR (Tables 2 and
3). Mapping on the TCR structure the effects of the mutation
on Kd (Figure 2B) revealed a central ‘‘hotspot’’ in the area
surrounding S99b residue; the hotspot consisted of D32b,
Q52b, and I53b, and R98b, mutation of which had a very adverse
effect on binding (Figure 2B). Curiously, however, themutation of
the S99b, which is located at the center of this hotspot, and in the
center of the binding interface, had little impact on the binding
affinity.
The D32bA mutation on CDR1b caused a 93% reduction in
binding affinity (Table 2). This substantial reduction reflected
the key role of the D32b side chain in binding the influenza-virus
matrix peptide, forming hydrogen bonds to peptide at T8 and
bridging a water molecule in the binding interface (Figures 2A
and 2C). The influenza-virus peptide mutation T8G also substan-
tially reduced the JM22 TCR binding affinity (data not shown),
such that the affinity became almost undetectable; however,
the T8G peptidemutationmay have induced change in the struc-
ture of the peptide.
The Q52bAmutation on CDR2b completely abrogated detect-
able binding. This result is consistent with the key structural role
of this residue, which formed two hydrogen bonds to the amino-
carboxyl backbone of the peptide at P4 and P6 (Figures 2A and
2C). Structurally, Q58b stabilized and orientated Q52b, in addi-
tion to forming a water-mediated bridge to the G4 carbonyl
group of the peptide. Mutation of Q58b to alanine resulted in
an approximate 50% decrease in binding affinity, almost all of
which can be attributed to a faster koff. Although Q58bE had
almost exactly the same affinity as the wild-type, it had a faster
koff counterbalanced by a faster kon. The thermodynamic dataFigure 1. Overview of Structural Changes
on Binding
(A) Relative shift of the JM22 Va domain to the
JM22 Vb domain in unliganded (red) and liganded
(green) forms. The twist is 7.0.
(B) The relative shift on binding in CDR3a loop res-
idues in relation to the Va domain.
(C) The relative shift on binding in CDR3b loop res-
idues in relation to the Vb domain.
(D) Positions of water molecules on the TCR bind-
ing surface from HLA-A2-flu unliganded (orange)
and from HLA-A2-flu complexed to JM22 (blue),
within 3.0 A˚ of pMHC and TCR.
(E) The relative temperature-factor changes for the
unliganded JM22 and HLA-A*0201-flu (left) com-
pared to the 1.4 A˚ resolution JM22-HLA-A*0201-
flu complex (right), colored from red (highest B
factor) to blue (lowest B factor) for main-chain
atoms.
Immunity
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favorable enthalpic effects, consistent with the loss of a water
bridge.
The N55bAmutation substantially decreased the binding affin-
ity by increasing the koff and decreasing the kon. Thermodynamic
analysis of the mutant revealed a substantially less favorable
change in binding enthalpy, partially compensated by a reduced
entropic penalty. TheD56bAmutation increased both the kon and
the koff, with little change in the affinity of binding. Both N55b and
D56b form parts of an extensive network with water molecules
that facilitated hydrogen bonding to HLA-A2 (Figures 2A and 2D).
Surprisingly, mutations of I53b generally had an adverse effect
on binding despite the fact that the I53 side chainmakes only van
der Waals contacts to the HLA-A2 a1 helix and peptide
(Figure 2A). Binding was partially restored by mutation to leucine
and almost completely restored by mutation to valine, suggest-
ing that this residue plays an important structural role in support-
ing the receptor in its bound state (discussed below).Figure 2. General Overview of JM22 Contact Residues and the
Effects of Mutations on Affinity for HLA-A2-flu
(A) Looking down at the HLA-A2-flu ligand, the peptide in yellow can be
seen to sit between the alpha helices of HLA-A2 in white. Portions of the
CDR loops of the JM22 TCR that contact the HLA-A2-flu ligand are col-
ored and labeled accordingly with CDR1a in pink, CDR3a in turquoise,
CDR1b in green, CDR2b in magenta, CDR3b in blue. The CDR2a loop is
excluded from the figure because it makes no direct contacts to the pep-
tide and minimal contacts to HLA-A2.
(B) Severity of the effects of mutations on KD are colored according to
a spectrum from adverse effects in red, orange, and yellow to mild effects
in green and blue. CDR3a residues that make main-chain contacts only at
the interface and were therefore not mutated are colored gray.
(C) Critical residues involved in direct and water-mediated hydrogen
bonds to peptide and HLA-A2 at the interface including Q58b, Q52b,
S99b, R98b, and D32b.
(D) Hydrogen-bond network maintained by N55b and D56b.
(E) CDR1a residues S31a, S32a, and Q34amaintain a water network sta-
bilizing R98b.
(F) The side chains of CDR3a residues A93a, G94a, and S95a. Q96a
and G97a make no direct contact to peptide or HLA-A2 and thus were
not selected for mutation. HLA-A2 is depicted in white, peptide
(GILGFVFTL) in yellow, CDR1a in pink, CDR3a in turquoise, CDR1b in
green, CDR2b in magenta, and CDR3b in blue.
The coselection of an arginine-serine motif at positions 98–
99 on the CDR3b has been identified as a key feature of the
Vb17 TCR immunodominant response (Lehner et al., 1995;
Moss et al., 1991; Stewart-Jones et al., 2003). In a sequence
analysis of thirteen different patients expressing 38 different
Vb17-bearing cytotoxic T cell clones in response to HLA-A2-
flu, 30 clones had the R98 residue and 32 clones had the S99
residue via variable codon usage, suggesting a strong selec-
tion pressure for both residues. Where the R98 residue was
not selected, in five of eight cases, Jb1.2 and a conserved
YGYTF motif were utilized, suggesting an alternative binding
strategy (Lehner et al., 1995). The crystal structure of the
JM22-HLA-A2-flu complex indicated that the R98b makes
four hydrogen bonds and slots into a ‘‘notch’’ on the surface
of the HLA-A2-flu complex (Figures 2A and 2C), and as ex-
pected, the R98bA mutation abrogated measurable binding.
The Y101bA mutation displayed a slight decrease in binding af-
finity but a markedly faster kon, consistent with the large confor-
mational adjustment observed for Y101b upon binding (see pre-
vious section) and the absence of stabilizing van der Waals
contacts conferred by this residue at the interface. The thermo-
dynamic data show a large entropic penalty compensated by
favorable enthalpic changes, which may indicate increased sol-
vent trapping in the large space vacated by the bulky tyrosine
residue.
The wild-type and S99bA mutant shared similar affinities.
Genetic data indicate that this residue is conserved (Lehner
et al., 1995), and it could be seen in the various JM22-HLA-A2-
flu complex crystal structures that S99 forms a direct hydrogen
bond to the peptide at V6 (Figures 2A and 2C). Therefore, it
was expected that binding affinity should be adversely affected
by mutation. However, the S99bA mutant has slightly increased
association and dissociation rates, increased heat-capacity
change, and a greatly decreased enthalpy and entropic penalty.Immunity 28, 171–182, February 2008 ª2008 Elsevier Inc. 175
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we determined the crystal structure of the S99bA mutant
receptor in complex with HLA-A2-flu to 2.3 A˚ resolution
(Figure S1). Three hydrogen bonds are absent in the mutant
structure, including one direct and one water-mediated hydro-
gen bond to the peptide at theG4 carbonyl, aswell as a hydrogen
bond to the amine group of Q52b. However, all remaining
hydrogen-bonding groups retained at least one partner in the
S99bA-HLA-A2-flu structure, and in comparisons of wild-type
and mutant structures, there was little observable shift in the
relative position of the interface water molecules.
One striking feature of WT JM22 TCR binding HLA-A2-flu is
that the binding kinetics were very temperature sensitive, with
the koff increasing dramatically with temperature (Willcox et al.,
1999). This temperature dependence was also observed with
the various JM22 mutants, including S99bA (Figure 3). An impor-
tant consequence of this temperature sensitivity is that absolute176 Immunity 28, 171–182, February 2008 ª2008 Elsevier Inc.differences in koff increased dramatically with temperature. Thus
the small absolute differences in koff between WT and S99bA
JM22 binding at 25C became much greater at physiological
temperatures (Figure 3 and Table 2). Because T cell activation
is believed to be strongly dependent on, and extremely sensitive
to, TCR koff (Matsui et al., 1994; Savage et al., 1999), these data
suggest that the relative absence of Vb17-S99bA receptors in
the population could result from their substantially faster koff at
physiological temperatures. Alternatively, the conservation of
the S99Ab residue may be due to genetic bias resulting from
the high frequency of serine codons (six available) or to preferen-
tial incorporation of particular nucleotides in the recombination
process (Venturi et al., 2006).
The main contribution of the codominant Va10.2 clonotype
appeared to be the water-mediated stabilization of the R98b
guanadinium headgroup by residues S31a, S32a, and Q34a
(Stewart-Jones et al., 2003) (Figures 2A and 2E). To test theTable 2. Affinity and Kinetics of JM22 Mutants Binding to HLA-A2-flu
TCR Mutation Kd (mM) kon (M
1s1) koff (s
1) koff (37C)
b (s1) Role of Original Amino Acid in Interface
WT 5.2 31000 0.16 1.5
CDR1b
D32A 74 Hydrogen bond to peptide T8
D32S >200 Hydrogen bond to peptide T8
CDR2b
Q52A >200 Two Hydrogen bonds to peptide at G4 and V6
Q52E >200 Two Hydrogen bonds to peptide at G4 and V6
I53A >200 Van der Waals contact to MHC a1 helix
I53G >200 Van der Waals contact to MHC a1 helix
I53N >200 Van der Waals contact to MHC a1 helix
I53V 7.3 17100 0.13 1.4 Van der Waals contact to MHC a1 helix
I53L 57 7000 0.40 Van der Waals contact to MHC a1 helix
N55A 35 18000 0.63 4.7 Water-mediated hydrogen bonding to MHC a1 helix
N55D 12 32300 0.38 Water-mediated hydrogen bonding to MHC a1 helix
D56A 6.5 38000 0.25 2.4 Water-mediated hydrogen bonding to MHC a1 helix
Q58A 12 28000 0.34 1.8 Stabilizes Q52b and forms water-mediated hydrogen
bond to peptide at G4
Q58E 5.2 50000 0.26 2.0 Stabilizes Q52b and forms water-mediated hydrogen
bond to peptide at G4
CDR3b
R98A >200 Four hydrogen bonds to MHC a2 helix
R98H >200 Four hydrogen bonds to MHC a2 helix
S99A 4.9 59000 0.29 4.0 Hydrogen bond to peptide at V6
Y101A 7.7 ~170000a ~1.3a ~30 Van der Waals contacts to a2 helix
Y101F 12 18000 0.21 0.7 Van der Waals contacts to a2 helix
CDR1a
S31A 15 13000 0.20 Water-mediated hydrogen bond to R98b
S32A 30 15000 0.46 7.2 Water-mediated hydrogen bond to R98b
Q34A 27 38000 1.03 13.7 Water-mediated hydrogen bonds to S32a and S100b
The Kd was determined by equilibrium-binding analysis, and kon was calculated as 10
6*koff/Kd. For some mutants, little or no binding was observed at
the highest TCR concentrations used (~200 mM), and the Kd was assumed to be > 200 mM.
a The koff measured for binding by the Y101bAmutant was close to the detection limit for the BIAcore; these koff and calculated kon values should there-
fore be considered approximations.
b Because the koff at 37
C were too fast to measure directly, they were estimated by measurement of koff at a range of lower temperatures and extrap-
olation to 37C via an Arrhenius plot.
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of S31aA, S32aA, and Q34aA mutants. S31aA or S32aA muta-
tions resulted in slower kon and faster koff rates. In the case of
S32aA, these alterations were associated with an increased
enthalpy and entropic penalty of binding. The Q34aA mutation
resulted in a somewhat increased kon, but a greatly increased
koff. Thus, although these residues enhance the binding process,
they are not necessary for it to occur.
The only CDR2a side chain to make contacts with the pMHC
is V51a; however, this mutant failed to refold. Only main-chain
atoms from the CDR3a loop (residues 94–97) contacted the
peptide, and the side chains of S95a and Q96a are orientated
into the solvent (Figure 2F). Thus, alanine scanning could not
be applied to this loop. Given that CDR3a undergoes a sub-
stantial conformational change upon binding (Figure 1B) and
makes direct contacts to the flu peptide at G4 (Figures 2Aand 2F), the length of the CDR3a may be important for peptide
recognition.
Multiple Complex Crystal Forms Reveal Various Angles
of TCR Engagement
To assess the range of possible structures the JM22:HLA-A2-flu
complex could adopt and how this may be important in TCR-
pMHC recognition, we determined the structures of two further
crystal forms of the complex. Thus these two crystal forms plus
the original complex structure provided in total three indepen-
dent views of JM22 bound to HLA-A2-flu. The TCR-pMHC inter-
face contacts were broadly identical for all of the structures.
However, the relative orientation (tilt) of the TCR when bound
to HLA-A2-flu varied by some 5. The protein-protein interac-
tions at the core of the interface were conserved for all of the
structures, whereas residues at the periphery accommodatedTable 3. Thermodynamics of JM22 Mutants Binding to HLA-A2-flu
TCR Mutant DG (kcal $ mol1) DH (kcal $ mol1) TDS (kcal $ mol1) DCP (kcal $ mol
1 $ K1) DzHD (kcal $ mol
1)
WT 7.2 23 ± 0.6 15 ± 0.6 0.64 ± 0.10 33 ± 0.5
CDR2b
I53V 7.0 22 ± 0.6 15 ± 0.6 0.63 ± 0.10 33 ± 0.7
N55A 6.1 18 ± 0.9 12 ± 0.9 0.33 ± 0.11 28 ± 3.6
D56A 7.1 24 ± 1.6s 17 ± 1.5 0.71 ± 0.15 32 ± 0.1
Q58A 6.7 18 ± 0.8 11 ± 0.8 0.32 ± 0.07 25 ± 2.1
Q58E 7.2 20 ± 0.4 13 ± 0.4 0.34 ± 0.05 30 ± 0.6
CDR3b
S99A 7.2 18 ± 0.5 10 ± 0.5 0.42 ± 0.06 30 ± 0.9
Y101A 7.0 29 ± 0.8 22 ± 0.8 1.1 ± 0.11 42 ± 0.0
Y101F 6.7 20 ± 0.3 13 ± 0.3 0.41 ± 0.04 29 ± 0.2
CDR1a
S32A 6.2 24 ± 0.8 18 ± 0.8 0.48 ± 0.07 37 ± 2.1
Q34A 6.2 23 ± 1.1 17 ± 1.1 1.1 ± 0.13 30 ± 4.6
Thermodynamics of JM22 mutants binding to HLA-A2-flu. All these values shown are for 25C and were measured as described previously (Lee et al.,
2004). In brief, DG was calculated from the Kd values; DH, TDS, and DCp were determined by nonlinear van’t Hoff analysis; D
zHD was determined by
Eyring analysis. The errors shown are the standard deviation of fit.Figure 3. The Variation of koff with Temperature for the Wild-
Type and Mutant Receptors JM22 Binding HLA-A2-flu
The high-activation enthalpies of dissociation for WT and mutant JM22
binding (see DzHD in Table 3) lead to large absolute differences at higher
temperatures. At 37C (310.15 K), the koff for WT and S99bA JM22 TCR
are estimated to be 1.5 s1 and 4 s1, respectively (Table 2).
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chain conformations, primarily at HLA-A2 Q72, Q155, and
R197 and TCR I53b. These results suggest that once bound to
theHLA-A2-flu, the JM22 forms a rigid unit that is capable of flex-
ing as a single entity from one tilt angle to another (Figure 4A).
Analysis of the 1.4 A˚ and the 2.4 A˚ resolution crystal forms re-
vealed that the pivot axis for the change in TCR tilt is positioned
at the conserved R98-S99 motif of the CDR3b loop (Figure 4B).
This region of the interface has the highest density of hydrogen
bonds, with R98b and S99b side chains saturating their hydro-
gen-bonding potential with interactions. In the 1.4 A˚ resolution
crystal form, where the TCR showed themost extreme tilt toward
the a1 helix, the CDR2b side chain I53b adjusted its conforma-
tion because of the reduced space between the CDR2b loop
and the a1 helix (Figure 4C). For this TCR orientation, the a1 helix
also flexed by up to 0.6 A˚ under the CDR2b loop compared to the
other crystal forms and the unliganded HLA-A2-flu structure,
indicating that the a1 helix can function as a ‘‘molecular shock
absorber’’ to accommodate some degree of flexibility at the
TCR-pMHC interface.
Binding studies of I53b mutants suggested that this residue
has a particular importance in stabilizing the ‘‘rocking’’ motion
of the TCR; I53bA, I53bG, and I53bN (N is a naturally occurring
amino acid at this position in other Vb frameworks) mutations
prevented binding entirely. It thus appeared that the spacing
that the I53b side chain imposes on the CDR2b-loop interface
with the a1 helix is precisely matched to that required to position
Q52b for optimal engagement with the peptide. The binding of
the I53bV and I53bL mutants supports the molecular-spacer178 Immunity 28, 171–182, February 2008 ª2008 Elsevier Inc.concept because valine is broadly similar to isoleucine. The extra
Cdmethyl group in I53b is not a major contributor to the interac-
tion spacing, and this mutation affects binding only slightly,
whereas the mutation to leucine, with its longer side chain,
disrupts binding substantially. Together, these data indicate
a model of binding in which the combination of the Q52b and
I53b side chains, which is not found in the germline of any other
human Vb domain, along with the CDR1b D32 side chain, is crit-
ical to the specific recognition of the HLA-A2-flu and provides
a basis for the immunodominant usage of the Vb17 framework
in the T cell response to the HLA-A2-flu.DISCUSSION
Public TCR usage is surprisingly common in many diseases, in-
cluding cytomegalovirs (CMV), EBV, HIV, and flu, in the context
of the large naive TCR repertoire from which these shared
TCRs are selected (Turner et al., 2006). TCR immunodominance
remains a perplexing phenomenon, contingent on factors as
diverse as antigen presentation, V(D)J recombination, thymic
selection, specificity, affinity, and activation. Here we have thor-
oughly investigated the structural flexibility and binding proper-
ties of a highly immunodominant human TCR clonotype that
emerges over a series of infections and clonal selection events
in response to influenza infection. We have identified key fea-
tures in the JM22-HLA-A2-flu that differ substantially from previ-
ous reports of TCR-pMHC complexes, which correlate with this
receptor’s extreme immunodominance and report dynamicFigure 4. Structural Variation of the JM22:HLA-A2-flu Complex
(A) Relative orientation (tilt) of JM22 on HLA-A2-flu for three different crystal forms: 1.4 A˚ (green), 2.4 A˚ (magenta), and 2.5 A˚ (blue). Although for the viewpoint of
this panel the JM22 tilt in the 2.5 A˚ complex appears intermediate between that in the other two complexes, this complex has an additional tilt component into the
plane of the paper.
(B) With the program Hingefind, CDR3b of the immunodominant Vb17 chain was identified as the pivot-point of the ‘‘rocking’’ motion; the schematic shows the
1.4 A˚ complex structure (gray) and the 2.4 A˚ structure (Va in red and Vb in blue).
(C) A comparison of the structures of the CDR2b loop (main chain and I53b side chain) and their interaction with the a1 helix of HLA-A2 for the 1.4 A˚ and 2.4 A˚
crystal forms. The flexion of the a1 helix at the CDR2b loop interface is not accompanied by any marked conformational changes in the helix-residue side chains,
and these are therefore omitted for clarity.
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tions more generally.
We utilized extensive kinetic and thermodynamic analyses to
identify the hotspot residues of TCR binding. The most crucial
hotspot residues in JM22 binding reside in the Vb17 domain
and include Q52b, I53b (CDR2), R98b (CDR3), and to a lesser
extent D32b (CDR1). This finding is consistent with earlier reports
that located the majority of hotspot residues in CDR1 and CDR2
loops, but it contrasts with a more recent study on an immuno-
dominant EBV-responding TCR inwhich the predominant contri-
butions were attributed to the CDR3 loops (Borg et al., 2005;
Gagnon et al., 2005; Lee et al., 2000; Manning et al., 1998). In
the JM22 complexes, the Vb domain contributes the entirety of
the hotspot of side chains crucial for binding and approximately
70% of the buried surface area in the bound complex, whereas
the Va domainmakes aminimal energetic contribution to binding
and is largely exposed to the solvent (Stewart-Jones et al., 2003).
This result contrasts with previous alanine-scanning studies that
have presented more balanced roles for the Va and Vb domains
(Borg et al., 2005; Gagnon et al., 2005; Lee et al., 2000; Manning
et al., 1998). In addition to the conformational changes in this re-
ceptor that lock the TCR onto its cognate pMHC, these hotspot
residues induced at the interface an observable ‘‘cooling’’ effect
that can be traced 15 A˚ into the TCR V domains. This observation
illustrates a clear entropy reduction (and conformational change)
induced by an enthalpic gain of interreceptor bonds.
From the structures of the complexes, the primary contribution
of the Va to binding the HLA-A2-flu is from the main chain of the
CDR3a loop, whereas the Va CDR1 and CDR2 loops are almost
completely exposed to the solvent. The germline-encoded por-
tion of the Vb17 CDR1 and CDR2 loops contribute substantially
to binding, in addition to the conserved CDR3 R98b and S99b
residues. Given that these two latter residues can be encoded
by the greatest number of codons, it seems plausible that the
precursor frequency of Vb17 receptors, bearing R98b and
S99b, that are capable of binding the HLA-A2-flu is higher
than other HLA-A2-flu-specific TCRs, and this may underpin
the public and immunodominant characteristics of this TCR
clonotype.
Surprisingly, although the S99b residue is surrounded by the
hotspot residues, R98b, D32b, Q52b, and I53b, and is consis-
tently selected in Vb17 flu-responding clonotypes, the affinity
of the S99bA mutant at 25C was similar to wild-type affinity.
The similarity in affinity was characterized by slightly faster kon
and koff rates for the S99bA mutant and by a loss of three hydro-
gen bonds from the structure. The consistent selection of the
S99b residue when there is more or less random generation of
sequence in the CDR3b may be a result of genetic bias in the
V(D)J recombination process (Venturi et al., 2006); examination
of the original data indicates that this mechanism is consistent
with the codon usage for this CDR3 loop (Lehner et al., 1995),
where the R98b is preferentially encoded by CGG (11/30) or
AGG (13/30) codons (there are six Arg codons) and S99b is pref-
erentially encoded by the AGC (18/29) codon (there are six Ser
codons). Alternatively, the preference for S99b over A99b may
be a result of faster binding kinetics, particularly at higher tem-
peratures in which the absolute difference is more pronounced.
These data suggest that caution should be taken in interpreting
SPR data collected at 25C, especially with influenza, where Tcells operate at a range of temperatures from cooler mucosal
surfaces (20C or lower) to core temperatures during fevers
(41–42) (Boron and Boulpaep, 2004). Studies have also sug-
gested that T cell proliferation in response to interleukins may
be many-fold higher at 39C than at 37 (Roberts, 1991). Thus,
difficulty in correlating kinetic binding, activation, and in vivo
data may derive not only from the measurement of binding at
25 rather than at 37C, but also from the necessity of accounting
for variable T cell activation and proliferative capacity in areas of
local temperature deviation.
Wecharacterized unligandedTCR, pMHC, and complex struc-
tures, providing a complete series of structures to understand
this system. Previous reports have demonstrated various de-
grees of CDR3-loop conformational change; however, in this
TCR-pMHC recognition process, the CDR3-loop conformational
change is accompanied by a Va-domain reorientation of 7,
a phenomenon that has only been observed to a minimal extent
in other TCR systems (Chen et al., 2005; Garcia et al., 1996; Kjer-
Nielsen et al., 2003; Reiser et al., 2002). This is a clear example of
a substantial structural change propagating from the antigen-
combining site toward the constant domains on cognate
pMHCbinding. If such a conformational change is involved in sig-
naling, it could conceivably participate in the immunodominance
of this receptor. However, the absence of this large-scale confor-
mational change in other TCRs studied thus far argues against
such a role. Additionally, the binding process induces a reorgani-
zation of the hydration shell within the TCR binding footprint on
the pMHC. Thus, the JM22 binding process involves CDR3-
loop rearrangement, a Va-domain reorientation propagating
a broad structural change of the Ca domain, a stabilization of
the TCR-antigen binding surface and framework, and remodeling
of the water structure within the interface. These changes enable
the TCR to make highly specific interactions that give rise to the
required affinity for the selection of this immunodominant TCR.
The multiple crystallographic snapshots of the JM22-HLA-A2-
flu complex structures revealed five variations in TCR binding
orientations. Similarly, Tynan et al. (2005) found two different
orientations of TCR to pMHC for the HLA-B*3508-EBV complex
crystal structure. This degree of variation suggests that a TCR
can approach a target pMHC from a range of different angles,
with docking facilitated by the conformational flexibility of the
CDR3 loops. Additionally, flexion at the interface suggests
a mechanism by which the TCR can disengage from its ligand,
where if the tilt angle becomes too extreme, bonds at the
interface are broken. Some support for the importance of this
‘‘rocking’’ motion may be inferred from the results of multiple
mutations to the I53b residue. The mutation of I53b to other res-
idues except valine considerably diminishes binding, suggesting
that it may act as a balance point to stabilize the rocking motion
centered on R98b and position theQ52b residue appropriately to
hydrogen bond to the peptide. Although TCR pivoting may be
a general phenomenon, the degree of receptor pivoting is likely
to correspond to the flexibility of individual TCR V domains and
of CDR3 loops and the fit of TCR to pMHC, and it may be of phys-
iological importance. Finally, this capacity for flexion may facili-
tate productive engagement with coreceptors in the immunolog-
ical synapse.
What are the structural and biophysical features of the JM22-
HLA-A2-flu system that lead to immunodominant selection of theImmunity 28, 171–182, February 2008 ª2008 Elsevier Inc. 179
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Molecular Basis for TCR ImmunodominanceVb17 clonotype? The range of structures presented here illus-
trates the dynamic nature of TCR recognition in greater detail
than has previously been possible. Given that three out of four
key residues important for binding the HLA-A2-flu are derived
from the Vb17 invariant CDR1 and CDR2 loops, a substantial
bias for the use of this clonotype is encoded in the germline.
The CDR3b thus requires minimal optimization by high-fre-
quency residues (as judged from codon usage) to corecognize
the pMHC in the context of this optimal variable domain. It
appears that these characteristics allow the Vb17 domain to
dominate the recognition surface of the HLA-A2-flu. The degree
of specificity of the JM22 for its relatively featureless, ‘‘plain
vanilla’’ (Davis, 2003) ligand is striking. That this exquisite spec-
ificity is largely encoded by the germline region of the Vb17
domain suggests that this domain may have coevolved with
the HLA-A2 to respond to the strong selection pressure of recur-
rent and often lethal influenza pandemics.
EXPERIMENTAL PROCEDURES
Protein Production and Purification
The engineering of a soluble form of the Vb17-Va10.2 immunodominant TCR
clone JM22 has been described previously (Stewart-Jones et al., 2003).
Mutations were introduced into this sequence by overlapping PCRwith T7 for-
ward and reverse primers and complementary primers engineered to contain
the desired mutation. All cloning was carried out in the Pett22b(+) vector
(Novagen). Mutant and wild-type TCRs were expressed with the E. coli strain
BLR (Novagen), isolated as inclusion bodies, purified, resolubilized, and
refolded as described. The refolded complexes were purified by anion
exchange, Ni+2, and gel-filtration chromatography, in which the wild-type
JM22 and all JM22 mutants purified were eluted at equivalent positions in
the final gel-filtration profile, indicating that monomeric refolded protein was
recovered. Receptor quality was confirmed by comparisons of the solubility,
chromatographic activity, and nonreduced and reduced SDS-PAGE profiles
to those of wild-type receptor prepared here and in previous work (Stewart-
Jones et al., 2003).
The peptide GILGFVFTLwas refoldedwith the HLA-A2 heavy chain with aC-
terminal biotinylation tag and b2M as described (Stewart-Jones et al., 2003).
For crystallography, HLA-A2 without a biotinylation tag was used for refolding.
Surface-Plasmon Resonance
SPR studies were performed with a BIAcore2000 as previously described
(Lee et al., 2004; Willcox et al., 1999). C-terminal biotinylated pMHC was im-
mobilized via covalently coupled streptavidin at levels of 1,200 to 1,600 RU.
Binding kinetics of the JM22 TCR is not substantially limited by mass trans-
fer at these immobilization levels (Willcox et al., 1999). Wild-type and mutant
forms of the JM22 TCR were injected over multiple flow cells, and the bind-
ing response was determined by subtraction of the response measured on
a control flow cell, which containing no pMHC, from the response measured
in flow cells containing pMHC. Affinity, kinetic, and thermodynamic parame-
ters were determined as previously described (Lee et al., 2004; Willcox et al.,
1999). Multiple kinetic datasets for most mutants were derived and were
consistent. For affinity measurements at temperatures other than 25C,
these were generally performed once, and where multiple measurements
were made, the data presented are from single representative measure-
ments.
Crystallization and Data Collection
All crystallizations were performed with the sitting-drop vapor-diffusion tech-
nique, typically with drops containing 1 ml of protein solution and 1 ml of reser-
voir solution. Single JM22-A2-flu complex crystals of three different crystal
forms grew at room temperature from a stoichiometric ratio of pMHC:TCR at
a final concentration of 10 mg/ml in 12% PEG8000, 50 mM MES (pH 7.4)
(2.4 A˚ and 3.65 A˚ structures); 11% PEG8000, 50 mM MES (pH 7.2); and
20% PEG3350, 200 mM NaI (pH 7.2) (2.5 A˚ structure); the S99bA JM22-180 Immunity 28, 171–182, February 2008 ª2008 Elsevier Inc.HLA-A2-flu complex crystallized in 14% PEG 8000, 100 mM MES (pH 6.1),
1M NaCl. The JM22 TCR crystallized in 20% ammonium sulfate, 100 mM
sodium cacodylate, pH 6.4 at 4C. The HLA-A2-flu crystals grew from 12%
PEG 8000, 100 mM MES pH 6.5 at room temperature.
Crystals were soaked briefly and sequentially in reservoir solutions contain-
ing 10% and 20% glycerol and then flash-cooled and maintained at 100K in
a cryostream (Oxford Cryosystem). All datasets were collected on station
ID14.2 at the European Synchrotron Radiation Facility (ESRF; Grenoble,
France) equipped with ADSC-q4 (Area Detector Systems Corporation, San
Diego) charged-couple device (CCD) detectors except for one JM22-HLA-
A2-flu complex crystal form diffracting to 3.65 A˚ with the in-house Rigaku
rotating anode generator (model RU-H3R) fitted with ‘‘osmic blue’’ confocal
optics and a mar345 detector. Although diffraction from this crystal was
weak, a clear molecular-replacement solution for TCR and pMHC could be
obtained. Details of the crystal space groups and unit cells are given below
and in Table 1. Datasets was autoindexed and integrated with the program
DENZO, followed by scaling with the program SCALEPACK (Otwinowski
and Minor, 1997).
Structure Determination and Refinement
All structures were determined by molecular replacement using the program
EPMR (Kissinger et al., 1999). For the JM22-HLA-A2-flu complex crystal forms,
an initial molecular-replacement solution was obtained through use of HLA-A2
heavy chain and b2M from 1OGA followed by a second round of molecular re-
placement using the 1OGA TCR while maintaining the HLA-A2/b2 M solution
as a partial static flag. The unliganded JM22 TCR structure was determined
by molecular replacement using the 1OGA TCR as an initial search model,
and the unliganded HLA-A2-flu was determined by molecular replacement
using the 1OGA HLA-A2-flu component as an initial search model.
With CNS (Brunger et al., 1998) the models were subjected to several
rounds of rigid-body refinement of individual domains (a1a2, a3, b2M, pep-
tide, Va, Vb, Ca, and Cb). For the 3.65 A˚ resolution JM22-HLA-A2-flu complex
structure, refinement proceeded no further than rigid-body refinement in RE-
FMAC5 (data not shown; space group C2; unit-cell dimensions [a, b, c] 242.4
A˚, 47.9 A˚, 186.5 A˚; cell angles [a, b, g] 90, 115, 90). For all other structures,
rounds of refinement were carried out with standard CNS protocols for bulk
solvent correction and overall anisotropic B factor scaling, positional refine-
ment, simulated annealing, and individual B factor refinement. Manual refitting
of the models was carried out with the program O (Jones et al., 1991). Final
stages of refinement, after water picking with ARP/wARP (Morris et al.,
2002), were done with a restrained translation liberation screw (TLS) refine-
ment algorithm in REFMAC5 (Murshudov et al., 1997). All regions of the
models’ densities were clear, except for the regions a146–a148 and a156–
a169 in the unliganded JM22 TCR, which were omitted from the TCR model.
Figure 2 and Figure S1 were produced with Pymol. Figure 3 was produced
with the statistics package Origin, version 5.0. Figures 1A–1C were produced
with Bobscript (Esnouf, 1999), Figure 1D was produced with Pymol (DeLano,
2002), Figure 4B was produced with Hingefind (Wriggers and Schulten, 1997),
and Figure 4A was produced with visual motor dynamics (VMD) (Humphrey
et al., 1996).
Supplemental Data
Four figures are available at http://www.immunity.com/cgi/content/full/28/2/
171/DC1/.
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